Cooper W D, Doyle G D, Donohoe J, Laher M, Ledingham J G, Raine A E, Melinck C, Unsworth J, Raman G V, VandenBurg M J
Merck Sharp and Dohme Limited, Hoddesdon, UK.
J Hypertens Suppl. 1985 Dec;3(3):S471-4.
This pilot study was undertaken to examine the safety and efficacy of enalapril in the treatment of hypertension associated with impaired renal function. Forty-one patients with glomerular filtration rate (GFR) < or = 50 ml/min received enalapril for up 12 weeks. Blood pressure, renal function, biochemistry and haematology were monitored weekly for 4 weeks and then monthly. Blood pressure was effectively reduced within 4 weeks; this reduction was maintained for at least 12 weeks. Renal function remained stable and there was no significant sustained alteration in any biochemical or haematological parameter. Requirement for additional antihypertensive drugs was reduced during enalapril therapy. These data suggest that enalapril may have a useful role in the management of hypertension associated with renal impairment.
本初步研究旨在探讨依那普利治疗肾功能受损相关高血压的安全性和有效性。41例肾小球滤过率（GFR）≤50ml/分钟的患者接受依那普利治疗长达12周。在4周内每周监测血压、肾功能、生化指标和血液学指标，之后每月监测一次。血压在4周内有效降低，且这种降低维持了至少12周。肾功能保持稳定，任何生化或血液学参数均无显著持续变化。依那普利治疗期间对其他降压药物的需求减少。这些数据表明，依那普利在治疗肾功能损害相关高血压方面可能具有有益作用。
